abstract: PURPOSE: A recent threefold increase in laser treatment for advanced @entity989 ( @entity989 ) triggered a nationwide preschool ophthalmic and developmental status among extremely preterm survivors. Here, we discuss refraction and visual acuity. METHODS: Survivors (n  =  178) from a national birth cohort (February 2004 to March 2006) of gestational age <28  weeks (PT) and 56 @entity27915 ( @entity27915 ) controls attended for evaluation at age 4  years. Cycloplegic refraction and keratometry were achieved by Retinomax autokeratorefractor and visual acuities by symbol recognition (HOTV, logMAR). RESULTS: The refractive distribution presented a myopic tail (4.5%) and a hyperopic tail (11.9% >= +2.5 D) as special preterm features, and corneas were more curved. @entity940 and @entity9340 were only marginally increased, and visual acuities were generally good. Best-corrected binocular median logMAR visual acuity was 0.1 in @entity27915 and 0.2 in PT, in Snellen equivalents 0.8 and 0.63. Snellen acuity  <=0.5 occurred across the @entity989 subgroups, but mainly in those with at least @entity989 stage 3. Two @entity1 had @entity4064 . CONCLUSIONS: The overall fair outcome for refraction and function is in accordance with other recent northern Europe experience. The results differ in particular from the poorer ophthalmic outcomes reported in the pioneer US treatment studies (cryotherapy for @entity989 and ETROP). The diode laser ablations (n  =  32) appeared effective in our series; except one @entity1 , all treated subjects had good or fair social vision at the age of 4  years.

title: Refraction and visual acuity in a national Danish cohort of 4-year-old XXXX of extremely preterm delivery.

entities_list: @entity940 :: ('MESH:D001251', 'Disease') :: ['Astigmatism']

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'child']

entities_list: @entity9340 :: ('MESH:D015858', 'Disease') :: ['anisometropia']

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy of prematurity', 'ROP']

entities_list: @entity4064 :: ('MESH:D015354', 'Disease') :: ['low vision']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: BACKGROUNDS/AIMS: According to 7th AJCC TNM staging system, @entity1086 ( @entity1086 ) with @entity1600 ( @entity1600 ) @entity3 is classified as N1 or N2; thus making the stage IIIB (N1) or IVB (N2). Stage IIIB consists of N1 status with wide coverage of T1-3, but T3N1 group often showed poorer outcomes than T1-2N1 groups. This study intended to assess post-resection prognosis of T3N1 versus other stage III subgroups. METHODS: We selected 103 @entity1 from our institutional database of @entity1086 who underwent R0 resection between July 1996 and June 2009 and whose @entity1086 was confined to stage T3N0, T1-3N1 or T1-3N2. These @entity1 were stratified into five groups, namely, T3N0 (n=26), T1N1 (n=13), T2N1 (n=35), T3N1 (n=20) and T1-3N2 (n=9), and were followed for >= 5 years or until @entity204 . RESULTS: Surgical procedures were minor liver resection (n=53), minor liver resection with bile duct resection (n=23), major liver resection (n=12), major liver resection with bile duct resection (n=5), and hepatopancreatoduodenectomy (n=12). Mean follow-up period was 57.2  68.5 months. Overall 5-year survival rate based on all-cause @entity204 and @entity5 , respectively, was 57.7% and 60.6% in T3N0, 15.4% and 15.4% in T1N1 (n=13), 28.6% and 28.6% in T2N1 (n=35), 5.0% and 5.7% in T3N1 (n=20), and 22.2% and 22.2% in T1-3N2. The survival outcome of T3N1 group was the poorest among the four stage III groups and was comparable to that of stage IVB (p=0.53). CONCLUSIONS: The prognosis of T3N1 @entity1086 is unusually poor even after R0 resection, thus we suggest extensive @entity1600 may be necessary in @entity1 with T3 @entity5 for accurate prognostic evaluation and radical removal of potential nodal micrometastasis. Further validation of this result is necessary in large @entity1 populations from multiple centers.

title: Survival analysis following resection of AJCC XXXX based on different combinations of T and N stages.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer-associated death', 'tumors']

entities_list: @entity1600 :: ('MESH:D014388', 'Disease') :: ['LN', 'LN dissection', 'lymph node']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity1086 :: ('MESH:D005706', 'Disease') :: ['GBC', 'gallbladder carcinoma']

answer: @entity5 :: (MESH:D009369,Disease) :: ['stage III gallbladder carcinoma']


abstract: @entity409 ( @entity409 ) is characterized by a large number of @entity96 scattered throughout the liver parenchyma. We herein intend to present the beneficial effect of palliative fenestration treatment on quality of life in a @entity1 with symptomatic @entity409 . A 48-year-old female @entity1 had been followed up for 5 years for both @entity8 at another institution. During follow-up for last 1 year, we recognized that she had barely maintained her ability of function in daily activities due to progressive @entity1295 and @entity1353 on exertion. The @entity1 finally underwent surgical fenestration treatment. @entity45 in the enlarged liver were opened and the cyst walls were excised with electrocautery. No surgical complication occurred and the @entity1 was discharged 10 days after the open fenestration surgery. The total liver volume was 3,870 ml before surgery and 3,125 ml at 1 week after surgery, showing a volume reduction of 19.3%. After surgery, her performance status improved significantly. In the present case, significant improvement in quality of life and daily activity performance was achieved after open fenestration treatment over 18 months of follow-up without disease recurrence.

title: @entity96 in XXXX to improve quality of life: a case report and literature review.

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['polycystic liver and kidney diseases']

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['liver cysts']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['PCLD', 'Polycystic liver disease']

entities_list: @entity1295 :: ('MESH:D005221', 'Disease') :: ['worsening of fatigue']

entities_list: @entity45 :: ('MESH:D010181', 'Disease') :: ['Multiple cysts']

answer: @entity409 :: (MESH:D008107,Disease) :: ['polycystic liver disease']


abstract: @entity409 ( @entity409 ) is characterized by a large number of @entity96 scattered throughout the liver parenchyma. We herein intend to present the beneficial effect of palliative fenestration treatment on quality of life in a @entity1 with symptomatic @entity409 . A 48-year-old female @entity1 had been followed up for 5 years for both @entity8 at another institution. During follow-up for last 1 year, we recognized that she had barely maintained her ability of function in daily activities due to progressive @entity1295 and @entity1353 on exertion. The @entity1 finally underwent surgical fenestration treatment. @entity45 in the enlarged liver were opened and the cyst walls were excised with electrocautery. No surgical complication occurred and the @entity1 was discharged 10 days after the open fenestration surgery. The total liver volume was 3,870 ml before surgery and 3,125 ml at 1 week after surgery, showing a volume reduction of 19.3%. After surgery, her performance status improved significantly. In the present case, significant improvement in quality of life and daily activity performance was achieved after open fenestration treatment over 18 months of follow-up without disease recurrence.

title: XXXX in @entity409 to improve quality of life: a case report and literature review.

answer: @entity96 :: (MESH:D008113,Disease) :: ['Fenestration of liver cysts']


abstract: AIMS: To assess the efficacy of conventional treatment combined with bacterial lysate [OM-85 Broncho-Vaxom (BV)] in the prevention of @entity565 in @entity1 as well as its influence on the number of natural killer T (NKT) cells and their cytokine production. MATERIALS AND METHODS: Sixty @entity1 diagnosed with @entity565 were divided into either a BV-treated group (with oral OM-85 BV) or a conventional inhaled corticosteroid (ICS) group. The numbers of NKT cells and CD4+ NKT cells were measured in the peripheral blood by flow cytometry. The levels of @entity379 , @entity3646 , and @entity688 after the blood cells had been cultured with an NKT cell agonist were detected by ELISA. RESULTS: After therapy, @entity565 attacks were significantly decreased compared with before therapy in both groups. However, after therapy, @entity1729 were reduced compared with before therapy in the BV-treated group only. Additionally, the frequency of @entity565 attacks and use of antibiotics in the BV-treated group were lower than in the ICS group. With BV treatment, the numbers of peripheral blood NKT cells and CD4+ NKT cells were higher after therapy than before therapy. After therapy, the ratio of @entity379 / @entity3646 and @entity688 levels were increased in the BV-treated group, whereas @entity3646 was reduced in the BV-treated group compared with the ICS group. CONCLUSION: BV combined with conventional @entity565 treatment can prevent recurrent @entity1729 and suppress the severity of @entity565 attacks, possibly by altering the rates and cytokines of NKT cells.    2015 S. Karger AG, Basel.

title: Bacterial Lysate Increases the Percentage of Natural Killer T Cells in Peripheral Blood and Alleviates Asthma in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity1729 :: ('MESH:D012141', 'Disease') :: ['respiratory tract infections']

answer: @entity1 :: (9606,Species) :: ['Children']


abstract: OBJECTIVE: In @entity625 , macrophages invade the affected joint. Experimental @entity625 models have shown that macrophages also invade the dorsal root ganglia (DRGs) of the inflamed segments in which the perikarya of sensory neurons are located. It is unclear whether this macrophage invasion contributes to @entity158 and/or furthers @entity528 . The present study was undertaken to investigate how differently activated macrophages affect DRG neurons. METHODS: We determined the phenotype of macrophages in the DRGs of rats with @entity625 ( @entity625 ). In a DRG neuron-macrophage coculture system, we investigated whether differently activated macrophages (stimulated with either lipopolysaccharide [LPS]/interferon-y [IFNy], @entity5 @entity39 factor [ @entity1505 ], or @entity12718 ) damage DRG neurons and/or stimulate them to release the mediator @entity4655 ( @entity4655 ), which promotes @entity158 and @entity13624 . RESULTS: Macrophages in the DRGs of @entity35 with @entity625 showed the phenotype of @entity1505 -stimulated macrophages but did not express inducible @entity842 synthase, which was found in cultured macrophages only after LPS/IFNy activation. In neuron-macrophage cocultures, activation of macrophages stimulated DRG neurons to release @entity4655 within 1 hour, indicating neuronal activation by macrophages. Only 48-hour activation of macrophages with LPS/IFNy increased the neuronal cell death rate in culture, provided that the macrophages were in direct contact with DRG neurons. This effect was dependent on @entity842 . CONCLUSION: Macrophages have the potential to stimulate sensory neurons in the DRGs, and this may contribute to @entity158 . If they are classically activated, such as after LPS/IFNy stimulation, this may also further neuronal cell death. This is not the case in @entity625 but may occur in models involving @entity528 .

title: Effects of differently activated rodent macrophages on sensory neurons: implications for XXXX .

entities_list: @entity4655 :: ('24241(Tax:10116)', 'Gene') :: ['CGRP', 'calcitonin gene-related peptide']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['antigen-induced arthritis', 'AIA', 'arthritis']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'arthritis pain']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal damage', 'damage of sensory neurons']

entities_list: @entity13624 :: ('MESH:D020078', 'Disease') :: ['neurogenic inflammation']

answer: @entity158 :: (MESH:D010146,Disease) :: ['arthritis pain']


abstract: UNASSIGNED: Inflammatory phenotypes of @entity565 are associated with differences in disease characteristics. It is unknown whether these inflammatory phenotypes are reflected by the activation status of neutrophils in blood and sputum. We obtained peripheral blood and induced sputum from 21 @entity565 @entity1 and stratified our samples based on sputum @entity1712 resulting in two groups (>3% eosinophils: n  =  13,  <3%: n  =  8). Eosinophils and neutrophils from blood and sputum were analysed for expression of activation and degranulation markers by flow cytometry. Data were analysed by both classical, non-parametric statistics and a multi-dimensional approach, using principal component analysis (PCA). @entity1 with sputum @entity1712 were characterized by increased @entity565 control questionnaire (ACQ) scores and blood eosinophil counts. Both sputum neutrophils and eosinophils displayed an activated and degranulated phenotype compared to cells obtained from blood. Specifically, degranulation of all granule types was detected in sputum cells, combined with an increased expression of the activation markers (activated) @entity9536 ( @entity9536 ), @entity4634 ( @entity4634 ) ( @entity4634 ) and a decreased expression of @entity1196 . @entity7986 expression was only increased on sputum eosinophils. Surface marker expression of neutrophils was similar in the presence or absence of @entity1712 , either by single or multi-dimensional analysis. Sputum neutrophils were highly activated and degranulated irrespective of sputum @entity1712 . Therefore, we conclude that differences in granulocyte activation in sputum and/or blood are not associated with clinical differences in the two groups of @entity565 @entity1 . The finding of @entity4634 expression on sputum granulocytes suggests an immunomodulatory role of these cells in the tissue.

title: Similar activation state of neutrophils in sputum of XXXX @entity1 irrespective of sputum @entity1712 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophilia']

answer: @entity565 :: (MESH:D001249,Disease) :: ['asthma']


abstract: UNASSIGNED: Inflammatory phenotypes of @entity565 are associated with differences in disease characteristics. It is unknown whether these inflammatory phenotypes are reflected by the activation status of neutrophils in blood and sputum. We obtained peripheral blood and induced sputum from 21 @entity565 @entity1 and stratified our samples based on sputum @entity1712 resulting in two groups (>3% eosinophils: n  =  13,  <3%: n  =  8). Eosinophils and neutrophils from blood and sputum were analysed for expression of activation and degranulation markers by flow cytometry. Data were analysed by both classical, non-parametric statistics and a multi-dimensional approach, using principal component analysis (PCA). @entity1 with sputum @entity1712 were characterized by increased @entity565 control questionnaire (ACQ) scores and blood eosinophil counts. Both sputum neutrophils and eosinophils displayed an activated and degranulated phenotype compared to cells obtained from blood. Specifically, degranulation of all granule types was detected in sputum cells, combined with an increased expression of the activation markers (activated) @entity9536 ( @entity9536 ), @entity4634 ( @entity4634 ) ( @entity4634 ) and a decreased expression of @entity1196 . @entity7986 expression was only increased on sputum eosinophils. Surface marker expression of neutrophils was similar in the presence or absence of @entity1712 , either by single or multi-dimensional analysis. Sputum neutrophils were highly activated and degranulated irrespective of sputum @entity1712 . Therefore, we conclude that differences in granulocyte activation in sputum and/or blood are not associated with clinical differences in the two groups of @entity565 @entity1 . The finding of @entity4634 expression on sputum granulocytes suggests an immunomodulatory role of these cells in the tissue.

title: Similar activation state of neutrophils in sputum of @entity565 @entity1 irrespective of sputum XXXX .

answer: @entity1712 :: (MESH:D004802,Disease) :: ['eosinophilia']


abstract: UNASSIGNED: Inflammatory phenotypes of @entity565 are associated with differences in disease characteristics. It is unknown whether these inflammatory phenotypes are reflected by the activation status of neutrophils in blood and sputum. We obtained peripheral blood and induced sputum from 21 @entity565 @entity1 and stratified our samples based on sputum @entity1712 resulting in two groups (>3% eosinophils: n  =  13,  <3%: n  =  8). Eosinophils and neutrophils from blood and sputum were analysed for expression of activation and degranulation markers by flow cytometry. Data were analysed by both classical, non-parametric statistics and a multi-dimensional approach, using principal component analysis (PCA). @entity1 with sputum @entity1712 were characterized by increased @entity565 control questionnaire (ACQ) scores and blood eosinophil counts. Both sputum neutrophils and eosinophils displayed an activated and degranulated phenotype compared to cells obtained from blood. Specifically, degranulation of all granule types was detected in sputum cells, combined with an increased expression of the activation markers (activated) @entity9536 ( @entity9536 ), @entity4634 ( @entity4634 ) ( @entity4634 ) and a decreased expression of @entity1196 . @entity7986 expression was only increased on sputum eosinophils. Surface marker expression of neutrophils was similar in the presence or absence of @entity1712 , either by single or multi-dimensional analysis. Sputum neutrophils were highly activated and degranulated irrespective of sputum @entity1712 . Therefore, we conclude that differences in granulocyte activation in sputum and/or blood are not associated with clinical differences in the two groups of @entity565 @entity1 . The finding of @entity4634 expression on sputum granulocytes suggests an immunomodulatory role of these cells in the tissue.

title: Similar activation state of neutrophils in sputum of @entity565 XXXX irrespective of sputum @entity1712 .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: @entity626 ( @entity626 ) is typically a slowly progressive disorder; however, a subset of knees progress with @entity1170 . We aimed to describe magnetic resonance imaging (MRI) findings that are associated with accelerated @entity626 . We conducted a longitudinal descriptive study in the @entity571 Initiative cohort. We selected @entity1 who had no radiographic @entity626 at baseline with one of the following in the most severe knee: (1) accelerated @entity626 (progressed to end-stage @entity626 within 48 months), (2) common @entity626 , and (3) no @entity626 at all visits. We enriched the sample by selecting knees with a self-reported or suspected @entity3331 . A musculoskeletal radiologist blinded to group assignments but not to time sequence performed MRI readings for the visit before and after an injury. We assessed 38 @entity1 (knees), 66% were female, mean age 61 (9) years, and mean body mass index 28.5 (4.9) kg/m(2). Fifteen of 20 knees with no or common @entity626 , had no incident findings consistent with acute damage. Among the 18 knees with accelerated @entity626 most had incident findings: 13 (72%) had incident medial meniscal pathology with extrusion and 5 (28%) knees had @entity16 . Incident MRI findings that are associated with incident accelerated @entity626 are characterized by structural damage that compromises subchondral bone or the function of the meniscus. Recognizing meniscal extrusion and/or change in shape, lateral meniscal tear, or acute @entity16 may be vital for identifying individuals at risk for accelerated @entity626 .

title: Meniscal extrusion or XXXX characterize incident accelerated @entity571 : Data from the @entity571 Initiative.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants']

entities_list: @entity626 :: ('MESH:D020370', 'Disease') :: ['Knee osteoarthritis', 'KOA']

entities_list: @entity571 :: ('MESH:D010003', 'Disease') :: ['Osteoarthritis']

entities_list: @entity1170 :: ('MESH:C564983', 'Disease') :: ['dramatic rapidity']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['subchondral damage']

entities_list: @entity3331 :: ('MESH:D007718', 'Disease') :: ['knee injury']

answer: @entity16 :: (MESH:D009422,Disease) :: ['subchondral damage']


abstract: @entity626 ( @entity626 ) is typically a slowly progressive disorder; however, a subset of knees progress with @entity1170 . We aimed to describe magnetic resonance imaging (MRI) findings that are associated with accelerated @entity626 . We conducted a longitudinal descriptive study in the @entity571 Initiative cohort. We selected @entity1 who had no radiographic @entity626 at baseline with one of the following in the most severe knee: (1) accelerated @entity626 (progressed to end-stage @entity626 within 48 months), (2) common @entity626 , and (3) no @entity626 at all visits. We enriched the sample by selecting knees with a self-reported or suspected @entity3331 . A musculoskeletal radiologist blinded to group assignments but not to time sequence performed MRI readings for the visit before and after an injury. We assessed 38 @entity1 (knees), 66% were female, mean age 61 (9) years, and mean body mass index 28.5 (4.9) kg/m(2). Fifteen of 20 knees with no or common @entity626 , had no incident findings consistent with acute damage. Among the 18 knees with accelerated @entity626 most had incident findings: 13 (72%) had incident medial meniscal pathology with extrusion and 5 (28%) knees had @entity16 . Incident MRI findings that are associated with incident accelerated @entity626 are characterized by structural damage that compromises subchondral bone or the function of the meniscus. Recognizing meniscal extrusion and/or change in shape, lateral meniscal tear, or acute @entity16 may be vital for identifying individuals at risk for accelerated @entity626 .

title: Meniscal extrusion or @entity16 characterize incident accelerated XXXX : Data from the @entity571 Initiative.

answer: @entity571 :: (MESH:D010003,Disease) :: ['osteoarthritis']


abstract: @entity626 ( @entity626 ) is typically a slowly progressive disorder; however, a subset of knees progress with @entity1170 . We aimed to describe magnetic resonance imaging (MRI) findings that are associated with accelerated @entity626 . We conducted a longitudinal descriptive study in the @entity571 Initiative cohort. We selected @entity1 who had no radiographic @entity626 at baseline with one of the following in the most severe knee: (1) accelerated @entity626 (progressed to end-stage @entity626 within 48 months), (2) common @entity626 , and (3) no @entity626 at all visits. We enriched the sample by selecting knees with a self-reported or suspected @entity3331 . A musculoskeletal radiologist blinded to group assignments but not to time sequence performed MRI readings for the visit before and after an injury. We assessed 38 @entity1 (knees), 66% were female, mean age 61 (9) years, and mean body mass index 28.5 (4.9) kg/m(2). Fifteen of 20 knees with no or common @entity626 , had no incident findings consistent with acute damage. Among the 18 knees with accelerated @entity626 most had incident findings: 13 (72%) had incident medial meniscal pathology with extrusion and 5 (28%) knees had @entity16 . Incident MRI findings that are associated with incident accelerated @entity626 are characterized by structural damage that compromises subchondral bone or the function of the meniscus. Recognizing meniscal extrusion and/or change in shape, lateral meniscal tear, or acute @entity16 may be vital for identifying individuals at risk for accelerated @entity626 .

title: Meniscal extrusion or @entity16 characterize incident accelerated @entity571 : Data from the XXXX Initiative.

answer: @entity571 :: (MESH:D010003,Disease) :: ['Osteoarthritis']


abstract: OBJECTIVE: To investigate the prevalence of @entity28 in young adults and to analyze the influencing factors on renal functions and @entity644 in this population. METHODS: This study comprised civil servants between 20 and 39  years old, who received physical examinations at the First Affiliated Hospital of Fujian Medical University. The subjects were categorized into four groups based on age (20-24, 25-29, 30-34 and 35-39  years) and the number of risk factors they had ( @entity101 , @entity2299 , @entity4854 and @entity5052 ). The relationships between @entity28 and the prevalence of @entity644 , between @entity28 and risk factors and between estimated glomerular filtration rate (eGFR) and @entity644 were analyzed. RESULTS: Among the 2293 young civil servants, in @entity1 the prevalence of @entity28 was 33.3  % and @entity644 was 2.5  %. However in @entity1 the prevalence of @entity28 and @entity644 was 7.5  % and 1.7  %, respectively. The levels of blood pressure, serum uric acid (UA), cholesterol (TC), triglyceride (TG), fasting glucose (FBG) and low-density lipoprotein cholesterol (LDL-C) were lower and the level of serum high-density lipoprotein cholesterol (HDL-C) was higher in nonobese groups compared with obese groups. There were no significant differences in eGFR between the two groups. The eGFR in male subjects was associated with age, UA, body mass index (BMI), FBG, TC, TG, LDL and HDL, and in female subjects associated with UA, age, BMI, diastolic blood pressure, FBG and LDL. BMI in both males and females increased with the higher number of risk factors. Multiple regression analysis revealed that @entity101 , @entity2299 , @entity4854 and @entity5052 were independently associated with @entity28 . eGFR decreased with a higher number of risk factors. Obesity, blood pressure, @entity2299 , @entity4854 and @entity5052 were independently associated with @entity644 . CONCLUSION: Obesity can pose an independent risk factor for @entity644 in young adults. @entity101 , @entity2299 , @entity4854 and @entity5052 were independently associated with @entity28 . eGFR decreased with a higher number of risk factors.

title: Analysis of renal functions and XXXX in young obese adults.

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'Hypertension']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia']

entities_list: @entity5052 :: ('MESH:D033461', 'Disease') :: ['hyperuricemia']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']

answer: @entity644 :: (MESH:D011507,Disease) :: ['proteinuria']


abstract: BACKGROUND: A new reassortant @entity683 (H7N9) virus emerged early 2013 in eastern China. Exposure to H7N9 infected poultry at live bird markets (LBM) was implicated as the main risk factor for @entity1 @entity281 . We aimed to identify the role of LBM biosecurity indicators and poultry movement in the affected areas. METHODS: A cross-sectional survey was carried out in 24 LBMs at the beginning of H7N9 outbreak in all affected provinces. We used univariable analysis to identify the biosecurity factors associated with the H7N9 presence in LBMs and social network and spatial analysis to quantify the connectivity and geographic variation in the connectivity of poultry movements. RESULTS: @entity1573 were the predominant poultry species traded by affected LBMs. The presence of H7N9 in LBMs was significantly associated with the type of LBM and with LBMs that sold @entity1573 to other markets. The @entity1573 movements were significantly spatially clustered and was highest in counties from Jiangsu and Anhui provinces. CONCLUSION: LBM biosecurity and @entity1573 movement played an important role in the emergence of H7N9. This study identified highly connected areas in eastern China which continue to report @entity1 infections highlighting candidate areas for more detailed epidemiological investigations.

title: The role of live poultry movement and live bird market biosecurity in the epidemiology of XXXX (H7N9): A cross-sectional observational study in four eastern China provinces.

entities_list: @entity683 :: ('MESH:D007251', 'Disease') :: ['influenza A']

entities_list: @entity1573 :: ('9031', 'Species') :: ['Chickens', 'chicken']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

answer: @entity683 :: (MESH:D007251,Disease) :: ['influenza A']


abstract: One experiment was conducted in which radioactively labeled @entity10043 bases ( @entity5536 , @entity2774 , @entity3625 and @entity3624 ) were individually given intravenously to young adult @entity35 and the recovery of radioactivity in urine and gut, gut content and liver was measured at the end of the next 24 hours. The total recovery of radioactivity from orally and intravenously administered @entity5536 was measured in experiment 2. A third experiment measured the recoveries of radioactivity from oral and intravenous @entity5536 in a wider variety of tissues and organs than in experiment 1. The chemical identities of the urinary end products of the metabolism or orally and intravenously administered @entity5536 were compared in a fourth experiment. When purines were given intravenously, significantly more of the administered radioactivity was recovered in urine from @entity35 given @entity2774 , @entity3625 or @entity3624 compared with those given @entity5536 . The greater recoveries of radioactivity in urine were associated with smaller recoveries in tissues. A larger proportion of intravenously compared to orally administered radioactivity from @entity5536 was incorporated into all body tissues, and this was most pronounced in glandular and lymphoid tissues. The primary urinary end product of both orally and intravenously administered @entity5536 was allantoin. The absorption of individual purines from isolated @entity35 gut sacs was evaluated in a fifth experiment. A significant proportion of unaltered @entity5536 crossed the mucosal to serosal barrier of intestinal sacs whereas unaltered @entity2774 , @entity3625 or @entity3624 did not cross into the serosal fluid. These results show that the intestinal metabolism of dietary @entity5536 is uniquely different from that of @entity2774 , @entity3625 or @entity3624 .

title: Metabolism of orally and intravenously administered purines in XXXX .

entities_list: @entity3625 :: ('MESH:D019271', 'Chemical') :: ['hypoxanthine']

entities_list: @entity3624 :: ('MESH:D019820', 'Chemical') :: ['xanthine']

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: UNASSIGNED: Bladder and @entity703 are two representative cases of @entity5 that respond differentially to @entity136 . Previous studies have shown that @entity136 can trigger apoptosis in various @entity5 cells. Herein, we sought to investigate the impact of @entity136 on the expression levels of the @entity588 family members @entity588 , @entity589 , and @entity34487 and the apoptosis-related microRNAs @entity21175 , @entity26365 , @entity3373 , and @entity15743 in the @entity1 @entity150 cell lines @entity1 and @entity1 , respectively. @entity5 cells' viability as well as the IC50 doses of @entity136 were estimated by the @entity98 assay, while the detection of cleaved @entity12982 via Western blotting was used as an indicator of apoptosis. Furthermore, @entity1 and @entity1 cells' ability to recover from treatment was also monitored. Two different highly sensitive quantitative real-time RT-PCR methodologies were developed in order to assess the expression levels of @entity588 family genes and microRNAs. Exposure of @entity5 cells to @entity136 produced the IC50 values of 30 and 3 nM for @entity1 and @entity1 cells, correspondingly, while cleaved @entity12982 was detected only in @entity1 cells. @entity1 cells demonstrated the ability to recover from @entity136 treatment, whereas @entity1 cells' recovery capability was dependent on the initial time of exposure. @entity588 and @entity589 were significantly modulated in treated @entity1 cells. Instead, @entity1 cells exhibited alterations only in the latter, as well as in all studied microRNAs. Therefore, according to our data, bladder and @entity703 cells' response to @entity136 is accompanied by distinct alterations in the expression levels of their apoptosis-related genes and microRNAs.

title: @entity136 impacts differentially on XXXX cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and @entity588 family genes.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Cancer', 'tumors']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder and kidney cancer']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['renal cancer']

answer: @entity150 :: (MESH:D001749,Disease) :: ['bladder and kidney cancer']


abstract: UNASSIGNED: Bladder and @entity703 are two representative cases of @entity5 that respond differentially to @entity136 . Previous studies have shown that @entity136 can trigger apoptosis in various @entity5 cells. Herein, we sought to investigate the impact of @entity136 on the expression levels of the @entity588 family members @entity588 , @entity589 , and @entity34487 and the apoptosis-related microRNAs @entity21175 , @entity26365 , @entity3373 , and @entity15743 in the @entity1 @entity150 cell lines @entity1 and @entity1 , respectively. @entity5 cells' viability as well as the IC50 doses of @entity136 were estimated by the @entity98 assay, while the detection of cleaved @entity12982 via Western blotting was used as an indicator of apoptosis. Furthermore, @entity1 and @entity1 cells' ability to recover from treatment was also monitored. Two different highly sensitive quantitative real-time RT-PCR methodologies were developed in order to assess the expression levels of @entity588 family genes and microRNAs. Exposure of @entity5 cells to @entity136 produced the IC50 values of 30 and 3 nM for @entity1 and @entity1 cells, correspondingly, while cleaved @entity12982 was detected only in @entity1 cells. @entity1 cells demonstrated the ability to recover from @entity136 treatment, whereas @entity1 cells' recovery capability was dependent on the initial time of exposure. @entity588 and @entity589 were significantly modulated in treated @entity1 cells. Instead, @entity1 cells exhibited alterations only in the latter, as well as in all studied microRNAs. Therefore, according to our data, bladder and @entity703 cells' response to @entity136 is accompanied by distinct alterations in the expression levels of their apoptosis-related genes and microRNAs.

title: XXXX impacts differentially on @entity150 cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and @entity588 family genes.

answer: @entity136 :: (MESH:C056507,Chemical) :: ['Gemcitabine']


abstract: UNASSIGNED: Bladder and @entity703 are two representative cases of @entity5 that respond differentially to @entity136 . Previous studies have shown that @entity136 can trigger apoptosis in various @entity5 cells. Herein, we sought to investigate the impact of @entity136 on the expression levels of the @entity588 family members @entity588 , @entity589 , and @entity34487 and the apoptosis-related microRNAs @entity21175 , @entity26365 , @entity3373 , and @entity15743 in the @entity1 @entity150 cell lines @entity1 and @entity1 , respectively. @entity5 cells' viability as well as the IC50 doses of @entity136 were estimated by the @entity98 assay, while the detection of cleaved @entity12982 via Western blotting was used as an indicator of apoptosis. Furthermore, @entity1 and @entity1 cells' ability to recover from treatment was also monitored. Two different highly sensitive quantitative real-time RT-PCR methodologies were developed in order to assess the expression levels of @entity588 family genes and microRNAs. Exposure of @entity5 cells to @entity136 produced the IC50 values of 30 and 3 nM for @entity1 and @entity1 cells, correspondingly, while cleaved @entity12982 was detected only in @entity1 cells. @entity1 cells demonstrated the ability to recover from @entity136 treatment, whereas @entity1 cells' recovery capability was dependent on the initial time of exposure. @entity588 and @entity589 were significantly modulated in treated @entity1 cells. Instead, @entity1 cells exhibited alterations only in the latter, as well as in all studied microRNAs. Therefore, according to our data, bladder and @entity703 cells' response to @entity136 is accompanied by distinct alterations in the expression levels of their apoptosis-related genes and microRNAs.

title: @entity136 impacts differentially on @entity150 cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and XXXX family genes.

answer: @entity588 :: (596,Gene) :: ['BCL2']


abstract: PURPOSE: To report our experience with bilateral placement of @entity619 0.7 mg ( @entity9170 ) sustained-release intravitreal implant in the management of noninfectious posterior @entity1596 or macular @entity4 secondary to @entity2994 . METHODS: A retrospective chart review of @entity1 with bilateral noninfectious posterior @entity1596 and macular @entity4 secondary to @entity2994 who were treated with @entity9170 intravitreal implant was performed. Ocular side effects such as intraocular pressure (IOP), @entity231 , and tolerability of bilateral injections was reviewed. RESULTS: Twenty-two eyes of eleven @entity1 treated with a total of 32 @entity9170 implants were included. Ten of eleven @entity1 received bilateral implants due to active noninfectious @entity1596 while the other demonstrated macular @entity4 in @entity735 following separate central @entity2994 . Among the @entity1 with bilateral @entity1596 , the mean interval between @entity9170 implant in the initial eye and the subsequent @entity9170 in the fellow eye was 15.6 days (range 2-71 days). Seven of the ten @entity1 received the second implant in the fellow eye within 8 days of the initial implantation. None of the @entity1 had bilateral implantations on the same day. Seven eyes required reimplantation for recurrence of @entity32 (mean interval between first and repeat implantation was 6.00  2.39 months). Following single or, in the case of the aforementioned seven eyes, repeat @entity9170 implantation, all 20 uveitic eyes demonstrated clinical and/or angiographic evidence of decreased @entity32 in the form of reduction in vitreous cells on slit lamp ophthalmoscopy, macular @entity4 on ophthalmoscopy, or optical coherence tomography and/or disc and vascular leakage on @entity941 angiography. The mean follow-up for all eyes after initial implantation was 23.57 months (range 1-48 months). IOP was significantly higher (P=0.028) at 6 months (16.62 mmHg   5.97) but not (P=0.82) at most recent follow-up (14.9  3.37 mmHg) when compared with baseline (14.68  3.02 mmHg). Four eyes (18.2%) required initiation of IOP-lowering medications. During the follow-up period, no eyes underwent filtration or @entity231 extraction. No serious ocular adverse effects were noted during the follow-up period. CONCLUSION: In @entity1 with bilateral noninfectious posterior @entity1596 and macular @entity4 secondary to @entity2994 , bilateral injection of @entity9170 intravitreal implant was well tolerated and had an acceptable safety profile.

title: Efficacy and tolerability of bilateral sustained-release @entity619 intravitreal implants for the treatment of noninfectious posterior @entity1596 and macular XXXX secondary to @entity2994 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract']

entities_list: @entity2994 :: ('MESH:D012170', 'Disease') :: ['vein occlusion', 'retinal vein occlusion', 'retinal vein occlusions']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['both eyes']

entities_list: @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein']

answer: @entity4 :: (MESH:D004487,Disease) :: ['edema']


abstract: PURPOSE: To report our experience with bilateral placement of @entity619 0.7 mg ( @entity9170 ) sustained-release intravitreal implant in the management of noninfectious posterior @entity1596 or macular @entity4 secondary to @entity2994 . METHODS: A retrospective chart review of @entity1 with bilateral noninfectious posterior @entity1596 and macular @entity4 secondary to @entity2994 who were treated with @entity9170 intravitreal implant was performed. Ocular side effects such as intraocular pressure (IOP), @entity231 , and tolerability of bilateral injections was reviewed. RESULTS: Twenty-two eyes of eleven @entity1 treated with a total of 32 @entity9170 implants were included. Ten of eleven @entity1 received bilateral implants due to active noninfectious @entity1596 while the other demonstrated macular @entity4 in @entity735 following separate central @entity2994 . Among the @entity1 with bilateral @entity1596 , the mean interval between @entity9170 implant in the initial eye and the subsequent @entity9170 in the fellow eye was 15.6 days (range 2-71 days). Seven of the ten @entity1 received the second implant in the fellow eye within 8 days of the initial implantation. None of the @entity1 had bilateral implantations on the same day. Seven eyes required reimplantation for recurrence of @entity32 (mean interval between first and repeat implantation was 6.00  2.39 months). Following single or, in the case of the aforementioned seven eyes, repeat @entity9170 implantation, all 20 uveitic eyes demonstrated clinical and/or angiographic evidence of decreased @entity32 in the form of reduction in vitreous cells on slit lamp ophthalmoscopy, macular @entity4 on ophthalmoscopy, or optical coherence tomography and/or disc and vascular leakage on @entity941 angiography. The mean follow-up for all eyes after initial implantation was 23.57 months (range 1-48 months). IOP was significantly higher (P=0.028) at 6 months (16.62 mmHg   5.97) but not (P=0.82) at most recent follow-up (14.9  3.37 mmHg) when compared with baseline (14.68  3.02 mmHg). Four eyes (18.2%) required initiation of IOP-lowering medications. During the follow-up period, no eyes underwent filtration or @entity231 extraction. No serious ocular adverse effects were noted during the follow-up period. CONCLUSION: In @entity1 with bilateral noninfectious posterior @entity1596 and macular @entity4 secondary to @entity2994 , bilateral injection of @entity9170 intravitreal implant was well tolerated and had an acceptable safety profile.

title: Efficacy and tolerability of bilateral sustained-release @entity619 intravitreal implants for the treatment of noninfectious posterior XXXX and macular @entity4 secondary to @entity2994 .

answer: @entity1596 :: (MESH:D014605,Disease) :: ['uveitis']


abstract: PURPOSE: To report our experience with bilateral placement of @entity619 0.7 mg ( @entity9170 ) sustained-release intravitreal implant in the management of noninfectious posterior @entity1596 or macular @entity4 secondary to @entity2994 . METHODS: A retrospective chart review of @entity1 with bilateral noninfectious posterior @entity1596 and macular @entity4 secondary to @entity2994 who were treated with @entity9170 intravitreal implant was performed. Ocular side effects such as intraocular pressure (IOP), @entity231 , and tolerability of bilateral injections was reviewed. RESULTS: Twenty-two eyes of eleven @entity1 treated with a total of 32 @entity9170 implants were included. Ten of eleven @entity1 received bilateral implants due to active noninfectious @entity1596 while the other demonstrated macular @entity4 in @entity735 following separate central @entity2994 . Among the @entity1 with bilateral @entity1596 , the mean interval between @entity9170 implant in the initial eye and the subsequent @entity9170 in the fellow eye was 15.6 days (range 2-71 days). Seven of the ten @entity1 received the second implant in the fellow eye within 8 days of the initial implantation. None of the @entity1 had bilateral implantations on the same day. Seven eyes required reimplantation for recurrence of @entity32 (mean interval between first and repeat implantation was 6.00  2.39 months). Following single or, in the case of the aforementioned seven eyes, repeat @entity9170 implantation, all 20 uveitic eyes demonstrated clinical and/or angiographic evidence of decreased @entity32 in the form of reduction in vitreous cells on slit lamp ophthalmoscopy, macular @entity4 on ophthalmoscopy, or optical coherence tomography and/or disc and vascular leakage on @entity941 angiography. The mean follow-up for all eyes after initial implantation was 23.57 months (range 1-48 months). IOP was significantly higher (P=0.028) at 6 months (16.62 mmHg   5.97) but not (P=0.82) at most recent follow-up (14.9  3.37 mmHg) when compared with baseline (14.68  3.02 mmHg). Four eyes (18.2%) required initiation of IOP-lowering medications. During the follow-up period, no eyes underwent filtration or @entity231 extraction. No serious ocular adverse effects were noted during the follow-up period. CONCLUSION: In @entity1 with bilateral noninfectious posterior @entity1596 and macular @entity4 secondary to @entity2994 , bilateral injection of @entity9170 intravitreal implant was well tolerated and had an acceptable safety profile.

title: Efficacy and tolerability of bilateral sustained-release XXXX intravitreal implants for the treatment of noninfectious posterior @entity1596 and macular @entity4 secondary to @entity2994 .

answer: @entity619 :: (MESH:D003907,Chemical) :: ['dexamethasone']


abstract: PURPOSE: To report our experience with bilateral placement of @entity619 0.7 mg ( @entity9170 ) sustained-release intravitreal implant in the management of noninfectious posterior @entity1596 or macular @entity4 secondary to @entity2994 . METHODS: A retrospective chart review of @entity1 with bilateral noninfectious posterior @entity1596 and macular @entity4 secondary to @entity2994 who were treated with @entity9170 intravitreal implant was performed. Ocular side effects such as intraocular pressure (IOP), @entity231 , and tolerability of bilateral injections was reviewed. RESULTS: Twenty-two eyes of eleven @entity1 treated with a total of 32 @entity9170 implants were included. Ten of eleven @entity1 received bilateral implants due to active noninfectious @entity1596 while the other demonstrated macular @entity4 in @entity735 following separate central @entity2994 . Among the @entity1 with bilateral @entity1596 , the mean interval between @entity9170 implant in the initial eye and the subsequent @entity9170 in the fellow eye was 15.6 days (range 2-71 days). Seven of the ten @entity1 received the second implant in the fellow eye within 8 days of the initial implantation. None of the @entity1 had bilateral implantations on the same day. Seven eyes required reimplantation for recurrence of @entity32 (mean interval between first and repeat implantation was 6.00  2.39 months). Following single or, in the case of the aforementioned seven eyes, repeat @entity9170 implantation, all 20 uveitic eyes demonstrated clinical and/or angiographic evidence of decreased @entity32 in the form of reduction in vitreous cells on slit lamp ophthalmoscopy, macular @entity4 on ophthalmoscopy, or optical coherence tomography and/or disc and vascular leakage on @entity941 angiography. The mean follow-up for all eyes after initial implantation was 23.57 months (range 1-48 months). IOP was significantly higher (P=0.028) at 6 months (16.62 mmHg   5.97) but not (P=0.82) at most recent follow-up (14.9  3.37 mmHg) when compared with baseline (14.68  3.02 mmHg). Four eyes (18.2%) required initiation of IOP-lowering medications. During the follow-up period, no eyes underwent filtration or @entity231 extraction. No serious ocular adverse effects were noted during the follow-up period. CONCLUSION: In @entity1 with bilateral noninfectious posterior @entity1596 and macular @entity4 secondary to @entity2994 , bilateral injection of @entity9170 intravitreal implant was well tolerated and had an acceptable safety profile.

title: Efficacy and tolerability of bilateral sustained-release @entity619 intravitreal implants for the treatment of noninfectious posterior @entity1596 and macular @entity4 secondary to XXXX .

answer: @entity2994 :: (MESH:D012170,Disease) :: ['retinal vein occlusion']


abstract: INTRODUCTION: Knowledge of disease burden attributable to @entity344 (FGD) in travelers is lacking, despite the high incidence of @entity294 (TD) associated with increased FGD risk. One tool for assessing the impact of disease on health-related quality of life is the health utility index (HUI), which values health states based on preferential health outcomes. Health utilities can be used as preference weights in the estimation of quality-adjusted life-years (QALYs). METHODS: Six months following travel to Egypt or @entity233 , 120 US military personnel completed a survey on TD during deployment, health-related quality of life (SF-36), and the onset of functional @entity29 (Rome II). Elements from the SF-36 were used to develop SF-6D values, which were combined with health state valuations to enable calculation of HUI scores for each subject. Mean index scores were compared across functional outcomes, specific symptoms, and demographic profiles. RESULTS: The presence of FGD significantly reduced index scores, with @entity1744 ( @entity1744 ) and @entity2210 showing the greatest impact (-0.17 and -0.19, respectively) compared with those with no FGD (p < 0.05). Importantly, however, several individuals met multiple FGD outcome definitions. Additionally, a number of symptoms associated with abnormal bowel habits and abdominal pain were associated with reduced index scores regardless of outcome. CONCLUSION: FGD are associated with significant morbidity as assessed by HUIs. Given the strong link between TD and FGD as well as the large number of travelers from the developed to the developing world, additional study is needed to further understand this association and efforts aimed at primary disease prevention are warranted.

title: Establishment of Health Utility Indices for Post-Infectious Functional XXXX in Active Duty US Military.

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ["travelers' diarrhea"]

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['functional gastrointestinal disorders']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['bowel disorders']

entities_list: @entity2210 :: ('MESH:D004415', 'Disease') :: ['dyspepsia']

entities_list: @entity1744 :: ('MESH:D043183', 'Disease') :: ['irritable bowel syndrome', 'IBS']

answer: @entity344 :: (MESH:D005767,Disease) :: ['Gastrointestinal Disorders']


abstract: OBJECTIVE: To examine the current evidence regarding the effects of whole-body vibration (WBV) training in individuals with @entity626 ( @entity571 ). DATA SOURCES: We searched PubMed, CINAHL, Embase, Scopus, Physiotherapy Evidence Database (PEDro), and Science Citation Index for research articles published prior to January 2015 using the keywords whole body vibration, vibration training, and vibratory exercise in combination with the Medical Subject Heading @entity626 . STUDY SELECTION: This meta-analysis was restricted to randomized controlled trials published in the English language. The quality of the selected studies was assessed by the PEDro Scale. The risk of bias was assessed using the Cochrane collaboration's tool in the domain-based evaluation. We also evaluated the quality of each study based on the criteria given by the International Society of Musculoskeletal and Neuronal Interactions for reporting WBV intervention studies, consisting of 13 factors. DATA EXTRACTION: Descriptive data regarding subjects, design, intervention, WBV parameters, outcomes, and conclusions were collected from each study by 2 independent evaluators. The mean and SD of the baseline and final endpoint scores for @entity158 , stiffness, and function were extracted from the included studies. DATA SYNTHESIS: A total of 83 studies were found in the search. Of these, 5 studies met the inclusion criteria and were further analyzed. Four of these 5 studies reached high methodologic quality on the PEDro Scale. Overall, studies demonstrated mixed results in favor of additive effects of WBV for reducing @entity158 and improving function in knee @entity571 . There was considerable variation in the parameters of the WBV included in this systematic review. CONCLUSIONS: WBV training reduces @entity158 and improves function in individuals with knee @entity571 .

title: Therapeutic Effects of Whole-Body Vibration Training in Knee XXXX : A Systematic Review and Meta-Analysis.

entities_list: @entity626 :: ('MESH:D020370', 'Disease') :: ['knee osteoarthritis', 'osteoarthritis knee']

answer: @entity571 :: (MESH:D010003,Disease) :: ['Osteoarthritis']


abstract: OBJECTIVE: Prior studies suggest that percutaneous access for @entity1028 repair (pEVAR) offers significant operative and postoperative benefits compared with femoral cutdown (cEVAR). National data on this topic, however, are limited. We compared @entity1 selection and outcomes for elective pEVAR and cEVAR. METHODS: We identified all @entity1 undergoing either pEVAR (bilateral percutaneous access, whether successful or not) or cEVAR (at least one planned groin cutdown) for @entity1028 from January 2011 to December 2013 in the Targeted Vascular data set from the American College of Surgeons National Surgical Quality Improvement Program database. Emergent cases, @entity397 , cases with an iliac conduit, and cases with a preoperative wound @entity281 were excluded. Groups were compared by   (2) test or t-test or the Mann-Whitney test where appropriate. RESULTS: We identified 4112 @entity1 undergoing elective EVAR, 3004 cEVAR @entity1 (73%) and 1108 pEVAR @entity1 (27%). Of all EVAR @entity1 , 26% had bilateral percutaneous access; 1.0% had attempted percutaneous access converted to cutdown (4% of pEVARs); and the remainder had a planned cutdown, 63.9% bilateral and 9.1% unilateral. There were no significant differences in age, gender, @entity439 diameter, or prior open abdominal surgery. @entity1 undergoing cEVAR were less likely to have @entity712 (1.5% vs 2.4%; P  = .04) but more likely to undergo any concomitant procedure during surgery (32% vs 26%; P  < .01) than @entity1 undergoing pEVAR. Postoperatively, pEVAR @entity1 had shorter operative time (mean, 135 vs 152  minutes; P  < .01), shorter length of stay (median, 1  day vs 2  days; P  < .01), and fewer wound complications (2.1% vs 1.0%; P  = .02). On multivariable analysis, the only predictor of percutaneous access failure was performance of any concomitant procedure (odds ratio, 2.0; 95% confidence interval, 1.0-4.0; P  = .04). CONCLUSIONS: Currently, one in four @entity1 treated at Targeted Vascular National Surgical Quality Improvement Program centers are getting pEVAR, which is associated with a high success rate, shorter operation time, shorter length of  stay, and fewer wound complications compared with cEVAR.

title: Percutaneous versus femoral cutdown access for XXXX repair.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['ruptures']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysm']

entities_list: @entity1028 :: ('MESH:D017544', 'Disease') :: ['abdominal aortic aneurysms', 'endovascular abdominal aortic aneurysm']

answer: @entity439 :: (MESH:D000783,Disease) :: ['endovascular aneurysm']


abstract: The physiological role of Ito has yet to be clarified. The goal of this study is to investigate the possible contribution of the transient outward current (Ito) on the generation of transmembrane action potentials (APs) and the sensitivity of @entity19 sinoauricular node (SAN) cells to a @entity973 ( @entity974 ) as Ito blocker. The electrophysiological identification of cells was performed in the sinoauricular node artery area (nstrips  =  38) of the subendocardial surface using microelectrode technique. In this study, for the first time, it was observed that dependence duration of action potential at the level of 20% repolarization (APD20) level under a @entity974 concentration in the pacemaker SAN and auricular cells corresponds to a curve predicted by Hill's equation. APD20 raised by 70% and spike duration of AP increased by 15-25%, when @entity974 concentration was increased from 0.1 to 5.0  mmol/L. Auricular cells were found to be more sensitive to @entity974 than true pacemaker cells. This was accompanied by a decrease in the upstroke velocity as compared to the control. Our data and previous findings in the literature lead us to hypothesize that the @entity974 -sensitive current participates in the repolarization formation of pacemaker and auricular type cells. Thus, study concerning the inhibitory effects of @entity3303 and @entity4524 on APD20 can explain the phenomenon of the decrease in upstroke velocity, which, for the first time, was observed after exposure to @entity974 . Duration of AP at the level of 20% repolarization (APD20) under a 4-AP concentration 0.5  mmol/L in the true pacemaker cells lengthen by 60-70% with a control.

title: Effects of XXXX on action potentials generation in @entity19 sinoauricular node strips.

entities_list: @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lidocaine']

entities_list: @entity973 :: ('MESH:D015761', 'Chemical') :: ['4-aminopyridine']

answer: @entity973 :: (MESH:D015761,Chemical) :: ['4-aminopyridine']


abstract: The physiological role of Ito has yet to be clarified. The goal of this study is to investigate the possible contribution of the transient outward current (Ito) on the generation of transmembrane action potentials (APs) and the sensitivity of @entity19 sinoauricular node (SAN) cells to a @entity973 ( @entity974 ) as Ito blocker. The electrophysiological identification of cells was performed in the sinoauricular node artery area (nstrips  =  38) of the subendocardial surface using microelectrode technique. In this study, for the first time, it was observed that dependence duration of action potential at the level of 20% repolarization (APD20) level under a @entity974 concentration in the pacemaker SAN and auricular cells corresponds to a curve predicted by Hill's equation. APD20 raised by 70% and spike duration of AP increased by 15-25%, when @entity974 concentration was increased from 0.1 to 5.0  mmol/L. Auricular cells were found to be more sensitive to @entity974 than true pacemaker cells. This was accompanied by a decrease in the upstroke velocity as compared to the control. Our data and previous findings in the literature lead us to hypothesize that the @entity974 -sensitive current participates in the repolarization formation of pacemaker and auricular type cells. Thus, study concerning the inhibitory effects of @entity3303 and @entity4524 on APD20 can explain the phenomenon of the decrease in upstroke velocity, which, for the first time, was observed after exposure to @entity974 . Duration of AP at the level of 20% repolarization (APD20) under a 4-AP concentration 0.5  mmol/L in the true pacemaker cells lengthen by 60-70% with a control.

title: Effects of @entity973 on action potentials generation in XXXX sinoauricular node strips.

answer: @entity19 :: (10090,Species) :: ['mouse']


abstract: BACKGROUND: It has been suggested that perturbations in branched-chain @entity535 (BCAA) catabolism are associated with insulin resistance and contribute to elevated systemic BCAAs. Evidence in rodents suggests dietary protein rich in BCAAs can increase BCAA catabolism, but there is limited evidence in @entity1 . OBJECTIVE: We hypothesize that a diet rich in BCAAs will increase BCAA catabolism, which will manifest in a reduction of fasting plasma BCAA concentrations. METHODS: The metabolome of 27 @entity28 @entity1 with @entity209 before and after weight loss was investigated to identify changes in BCAA metabolism using GC-time-of-flight mass spectrometry. Subjects were enrolled in an 8-wk weight-loss study including either a 20-g/d whey (whey group, n = 16) or gelatin (gelatin group, n = 11) protein supplement. When matched for total protein by weight, whey protein has 3 times the amount of BCAAs compared with gelatin protein. RESULTS: Postintervention plasma abundances of Ile (gelatin group: 637    18, quantifier ion peak height    100; whey group: 744    65), Leu (gelatin group: 1210    33; whey group: 1380    79), and @entity2596 (gelatin group: 2080    59; whey group: 2510    230) did not differ between treatment groups. BCAAs were significantly correlated with homeostasis model assessment of insulin resistance at baseline (r = 0.52, 0.43, and 0.49 for Leu, Ile, and @entity2596 , respectively; all, P < 0.05), but correlations were no longer significant at postintervention. Pro- and @entity2569 -related pathways were found discriminant of whey protein vs. gelatin protein supplementation in multivariate statistical analyses. CONCLUSIONS: These findings suggest that BCAA metabolism is, at best, only modestly affected at a whey protein supplementation dose of 20 g/d. Furthermore, the loss of an association between postintervention BCAA and homeostasis model assessment suggests that factors associated with calorie restriction or protein intake affect how plasma BCAAs relate to insulin sensitivity. This trial was registered at clinicaltrials.gov as NCT00739479.

title: Whey Protein Supplementation Does Not Alter Plasma Branched-Chained XXXX Profiles but Results in Unique Metabolomics Patterns in Obese @entity1 Enrolled in an 8-Week Weight Loss Trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'humans']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome']

answer: @entity535 :: (CHEBI:33704,Chemical) :: ['Amino Acid']


abstract: BACKGROUND: It has been suggested that perturbations in branched-chain @entity535 (BCAA) catabolism are associated with insulin resistance and contribute to elevated systemic BCAAs. Evidence in rodents suggests dietary protein rich in BCAAs can increase BCAA catabolism, but there is limited evidence in @entity1 . OBJECTIVE: We hypothesize that a diet rich in BCAAs will increase BCAA catabolism, which will manifest in a reduction of fasting plasma BCAA concentrations. METHODS: The metabolome of 27 @entity28 @entity1 with @entity209 before and after weight loss was investigated to identify changes in BCAA metabolism using GC-time-of-flight mass spectrometry. Subjects were enrolled in an 8-wk weight-loss study including either a 20-g/d whey (whey group, n = 16) or gelatin (gelatin group, n = 11) protein supplement. When matched for total protein by weight, whey protein has 3 times the amount of BCAAs compared with gelatin protein. RESULTS: Postintervention plasma abundances of Ile (gelatin group: 637    18, quantifier ion peak height    100; whey group: 744    65), Leu (gelatin group: 1210    33; whey group: 1380    79), and @entity2596 (gelatin group: 2080    59; whey group: 2510    230) did not differ between treatment groups. BCAAs were significantly correlated with homeostasis model assessment of insulin resistance at baseline (r = 0.52, 0.43, and 0.49 for Leu, Ile, and @entity2596 , respectively; all, P < 0.05), but correlations were no longer significant at postintervention. Pro- and @entity2569 -related pathways were found discriminant of whey protein vs. gelatin protein supplementation in multivariate statistical analyses. CONCLUSIONS: These findings suggest that BCAA metabolism is, at best, only modestly affected at a whey protein supplementation dose of 20 g/d. Furthermore, the loss of an association between postintervention BCAA and homeostasis model assessment suggests that factors associated with calorie restriction or protein intake affect how plasma BCAAs relate to insulin sensitivity. This trial was registered at clinicaltrials.gov as NCT00739479.

title: Whey Protein Supplementation Does Not Alter Plasma Branched-Chained @entity535 Profiles but Results in Unique Metabolomics Patterns in Obese XXXX Enrolled in an 8-Week Weight Loss Trial.

answer: @entity1 :: (9606,Species) :: ['Women']


abstract: BACKGROUND: @entity1944 ( @entity1944 ) is poorly understood. Animal experiments suggest that @entity8302 ( @entity8302 ), play an important role. METHODS: @entity1 with @entity6675 ( @entity6675 ) and @entity1944 (time to full feed >42days) were selected. Age matched @entity6675 and control (NEC, @entity4628 , @entity1518 , and @entity3313 ) samples from primary (T1) and secondary (T2) time points underwent standard histopathology and immunohistochemistry for identification of @entity8302 , followed by evaluation of @entity8302 numbers, distribution, morphology, relation to ganglion cells, and myenteric plexus architecture. Groups were compared using parametric and nonparametric tests. MAIN RESULTS: Twelve @entity1 had samples available for histopathological evaluation. @entity1944 @entity1 had a significantly lower total number of ICCs than controls (3 vs. 8, P<0.0029). @entity8302 number at T1 was 2.5 vs. 6 (P=0.0629) and significantly lower at T2. (3.5 vs. 11, P=0.0124). @entity1944 @entity1 did not show a significant increase of @entity8302 from T1 to T2. Controls showed a significant increase of @entity8302 over time (6 vs. 11, P=0.0408). CONCLUSION: Intestinal samples from @entity1 with @entity1944 who underwent stoma formation demonstrated fewer @entity8302 than controls. There was no improvement or cell recovery during the study period. The ability to modulate @entity8302 may have significant implications for the management of @entity1944 .

title: Interstitial cells of Cajal are decreased in @entity1 with @entity6675 associated XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'infants', 'Infants']

entities_list: @entity1944 :: ('MESH:D007410', 'Disease') :: ['Gastroschisis associated intestinal dysmotility', 'GAID']

entities_list: @entity4628 :: ('MESH:D007077', 'Disease') :: ['ileal atresia']

entities_list: @entity1518 :: ('MESH:C562835', 'Disease') :: ['malrotation']

entities_list: @entity6675 :: ('MESH:D020139', 'Disease') :: ['GS', 'gastroschisis']

entities_list: @entity8302 :: ('MESH:D007984', 'Disease') :: ['ICC', 'interstitial cells of Cajal']

answer: @entity1944 :: (MESH:D007410,Disease) :: ['intestinal dysmotility']


abstract: BACKGROUND: @entity1944 ( @entity1944 ) is poorly understood. Animal experiments suggest that @entity8302 ( @entity8302 ), play an important role. METHODS: @entity1 with @entity6675 ( @entity6675 ) and @entity1944 (time to full feed >42days) were selected. Age matched @entity6675 and control (NEC, @entity4628 , @entity1518 , and @entity3313 ) samples from primary (T1) and secondary (T2) time points underwent standard histopathology and immunohistochemistry for identification of @entity8302 , followed by evaluation of @entity8302 numbers, distribution, morphology, relation to ganglion cells, and myenteric plexus architecture. Groups were compared using parametric and nonparametric tests. MAIN RESULTS: Twelve @entity1 had samples available for histopathological evaluation. @entity1944 @entity1 had a significantly lower total number of ICCs than controls (3 vs. 8, P<0.0029). @entity8302 number at T1 was 2.5 vs. 6 (P=0.0629) and significantly lower at T2. (3.5 vs. 11, P=0.0124). @entity1944 @entity1 did not show a significant increase of @entity8302 from T1 to T2. Controls showed a significant increase of @entity8302 over time (6 vs. 11, P=0.0408). CONCLUSION: Intestinal samples from @entity1 with @entity1944 who underwent stoma formation demonstrated fewer @entity8302 than controls. There was no improvement or cell recovery during the study period. The ability to modulate @entity8302 may have significant implications for the management of @entity1944 .

title: Interstitial cells of Cajal are decreased in @entity1 with XXXX associated @entity1944 .

answer: @entity6675 :: (MESH:D020139,Disease) :: ['gastroschisis']


abstract: BACKGROUND: @entity1944 ( @entity1944 ) is poorly understood. Animal experiments suggest that @entity8302 ( @entity8302 ), play an important role. METHODS: @entity1 with @entity6675 ( @entity6675 ) and @entity1944 (time to full feed >42days) were selected. Age matched @entity6675 and control (NEC, @entity4628 , @entity1518 , and @entity3313 ) samples from primary (T1) and secondary (T2) time points underwent standard histopathology and immunohistochemistry for identification of @entity8302 , followed by evaluation of @entity8302 numbers, distribution, morphology, relation to ganglion cells, and myenteric plexus architecture. Groups were compared using parametric and nonparametric tests. MAIN RESULTS: Twelve @entity1 had samples available for histopathological evaluation. @entity1944 @entity1 had a significantly lower total number of ICCs than controls (3 vs. 8, P<0.0029). @entity8302 number at T1 was 2.5 vs. 6 (P=0.0629) and significantly lower at T2. (3.5 vs. 11, P=0.0124). @entity1944 @entity1 did not show a significant increase of @entity8302 from T1 to T2. Controls showed a significant increase of @entity8302 over time (6 vs. 11, P=0.0408). CONCLUSION: Intestinal samples from @entity1 with @entity1944 who underwent stoma formation demonstrated fewer @entity8302 than controls. There was no improvement or cell recovery during the study period. The ability to modulate @entity8302 may have significant implications for the management of @entity1944 .

title: Interstitial cells of Cajal are decreased in XXXX with @entity6675 associated @entity1944 .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVES: (1) To explain general practitioners' (GPs') approaches to @entity1486 ( @entity1486 ) testing and overdiagnosis; (2) to explain how GPs reason about their @entity1486 testing routines and (3) to explain how these routines influence GPs' personal experience as clinicians. SETTING: Primary care practices in Australia including @entity1 's health clinics and rural practices with variable access to urology services. @entity1 : 32 urban and rural GPs within Australia. We included GPs of varying ages, gender (11 female), clinical experience and @entity1 populations. All GPs interested in participating in the study were included. PRIMARY AND SECONDARY OUTCOME MEASURES: Data were analysed using grounded theory methods to determine how and why GPs provide (or do not provide) @entity1486 testing to their asymptomatic male @entity1 . RESULTS: We observed patterned variation in GP practice, and identified four heuristics to describe GP preference for, and approaches to, @entity1486 testing and overdiagnosis: (1) GPs who prioritised avoiding underdiagnosis, (2) GPs who weighed underdiagnosis and overdiagnosis case by case, (3) GPs who prioritised avoiding overdiagnosis and (4) GPs who did not engage with overdiagnosis at all. The heuristics guided GPs' Routine Practice (usual testing, communication and responses to @entity1 request). The heuristics also reflected GPs' different Practice Rationales (drawing on experience, medicolegal obligations, guidelines and evidence) and produced different Practice Outcomes (GPs' experiences of the consequences of their @entity1486 testing decisions). Some of these heuristics were more responsive to @entity1 preferences than others. CONCLUSIONS: Variation in GPs' @entity1486 testing practices is strongly related to their approach to overdiagnosis and underdiagnosis of @entity263 . @entity1 receive very different care depending on their GP's reasoning and practice preferences. Future policy to address overdiagnosis will be more likely to succeed if it responds to these patterned variations.

title: Doctors' approaches to XXXX testing and overdiagnosis in primary healthcare: a qualitative study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Men', 'PARTICIPANTS', 'men']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

entities_list: @entity1486 :: ('354', 'Gene') :: ['PSA', 'prostate-specific antigen']

answer: @entity1486 :: (354,Gene) :: ['PSA']


abstract: Studying sleep behavior in animal models demands clear separation of vigilance states. Pure manual scoring is time-consuming and commercial scoring software is costly. We present a LabVIEW-based, semi-automated scoring routine using recorded EEG and EMG signals. This scoring routine is    designed to reliably assign the vigilance/sleep states @entity1442 ( @entity1442 ), @entity11755 ( @entity11755 ) and rapid eye @entity10522 (REMS) to defined EEG/EMG episodes.   straightforward to use even for beginners in the field of sleep research.   freely available upon request. Chronic recordings from @entity19 were used to design and evaluate the scoring routine consisting of an artifact-removal, a scoring- and a rescoring routine. The scoring routine processes EMG and different EEG frequency bands. Amplitude-based thresholds for EEG and EMG parameters trigger a decision tree assigning each EEG episode to a defined vigilance/sleep state automatically. Using the rescoring routine individual episodes or particular state transitions can be re-evaluated manually. High agreements between auto-scored and manual sleep scoring could be shown for experienced scorers and for beginners quickly and reliably. With small modifications to the software, it can be easily adapted for sleep analysis in other animal models.

title: Sleep scoring made easy-Semi-automated sleep analysis software and manual rescoring tools for basic sleep research in XXXX .

entities_list: @entity11755 :: ('MESH:D020187', 'Disease') :: ['NREMS', 'non-rapid eye movement sleep']

entities_list: @entity10522 :: ('MESH:D020189', 'Disease') :: ['movement sleep']

entities_list: @entity1442 :: ('MESH:D020178', 'Disease') :: ['wakefulness', 'WAKE']

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: BACKGROUND: Little is known about the long-term outcomes of catheter ablation of @entity4710 ( @entity4710 ) using @entity262 ( @entity262 ). METHODS: One hundred twenty @entity1 underwent catheter ablation of SVTs with @entity262 (Niobe, Stereotaxis, USA): atrioventricular nodal re-entrant @entity591 (AVNRT; n   =   59), @entity591 ( @entity591 ; n   =   45), and focal @entity591 ( @entity591 , n   =   16). The outcome of @entity591 with right free wall accessory pathway was compared with those of a group of 26 consecutive @entity1 undergoing manual ablation. RESULTS: Mean follow-up period was 2.2        1.4  years. Overall @entity943 -free survival was 86  %; @entity591 (77  %), AVNRT (96  %), and focal @entity591 (71  %). After the learning period (initial 50 cases), procedural outcomes had improved for @entity591 and AVNRT (91  % in overall group, 90  % in @entity591 group, 100  % in AVNRT group, and 68  % in focal @entity591 group). The recurrence-free rate was higher for the free wall accessory pathways than those of the other sites (92 vs. 73  %, log-rank P   =   0.06). Furthermore, when it is confined for the right free wall accessory pathway, @entity262 showed excellent long-term outcome (7/7, 100  %) compared to the results of manual approach (18/26, 69.2  %, log-rank P   =   0.07). CONCLUSIONS: @entity262 showed favorable long-term outcomes for the ablation of @entity4710 . In our experience, @entity262 -guided ablation may be associated with a higher success rate as compared to manual ablation when treating right-sided free wall pathways.

title: Long-term outcomes of remote magnetic navigation for ablation of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity262 :: ('MESH:D034721', 'Disease') :: ['remote magnetic navigation system', 'RMN']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardia', 'atrial tachycardia', 'atrioventricular re-entrant tachycardia', 'AVRT', 'AT']

entities_list: @entity4710 :: ('MESH:D013617', 'Disease') :: ['supraventricular tachycardia', 'SVT']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia']

answer: @entity4710 :: (MESH:D013617,Disease) :: ['supraventricular tachycardias']


abstract: OBJECTIVES: Periorbital microcystic @entity600 ( @entity600 ) can cause severe symptoms, such as @entity1736 , @entity4457 , chemosis, strabismus, @entity4064 , and @entity1939 . The purpose of this study was to evaluate the clinical outcome in periorbital microcystic @entity600 @entity1 with @entity1736 who underwent surgical treatment combined with intralesional @entity1732 injection. @entity1 AND METHODS: A retrospective study including nine @entity1 diagnosed as periorbital microcystic @entity600 with @entity1736 was conducted. All of the @entity1 underwent surgical treatment and @entity1732 injection from January 2010 to January 2014. The lesion was resected through the lower eyebrow and/or a coronal incision at the first stage, and levator resection was performed at the second stage. Any persistent lesion or its recurrence was managed by intralesional @entity1732 injection. RESULTS: @entity1736 and @entity227 were corrected in all @entity1 . Mean follow-up was 24.6months. Six @entity1 had recurrence during the follow-up, and two @entity1 who had partial eyelid closure after the second stage surgery recovered in three months. @entity4457 , @entity940 , and strabismus were not improved after treatment. All of the @entity1 had excellent aesthetic improvement and corrected @entity1736 . CONCLUSIONS: Resection through a lower eyebrow and coronal incision and levator resection performed in two stages can quickly correct the @entity227 caused by periorbital microcystic @entity600 with @entity1736 . Intralesional @entity1732 injection is a promising adjunctive therapy for residual or recurrent lesions after surgery.

title: Management of periorbital microcystic @entity600 with @entity1736 : Surgical treatment combined with intralesional XXXX injection.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity940 :: ('MESH:D001251', 'Disease') :: ['astigmatism']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual impairment', 'visual obstruction']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['lymphatic malformation', 'lymphatic malformations', 'LM']

entities_list: @entity1939 :: ('MESH:D001766', 'Disease') :: ['blindness']

entities_list: @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin']

entities_list: @entity4064 :: ('MESH:D015354', 'Disease') :: ['diminished vision']

entities_list: @entity1736 :: ('MESH:D001763', 'Disease') :: ['Blepharoptosis', 'blepharoptosis']

entities_list: @entity4457 :: ('MESH:D000550', 'Disease') :: ['amblyopia', 'Amblyopia']

answer: @entity1732 :: (MESH:D001761,Chemical) :: ['bleomycin']


abstract: OBJECTIVES: Periorbital microcystic @entity600 ( @entity600 ) can cause severe symptoms, such as @entity1736 , @entity4457 , chemosis, strabismus, @entity4064 , and @entity1939 . The purpose of this study was to evaluate the clinical outcome in periorbital microcystic @entity600 @entity1 with @entity1736 who underwent surgical treatment combined with intralesional @entity1732 injection. @entity1 AND METHODS: A retrospective study including nine @entity1 diagnosed as periorbital microcystic @entity600 with @entity1736 was conducted. All of the @entity1 underwent surgical treatment and @entity1732 injection from January 2010 to January 2014. The lesion was resected through the lower eyebrow and/or a coronal incision at the first stage, and levator resection was performed at the second stage. Any persistent lesion or its recurrence was managed by intralesional @entity1732 injection. RESULTS: @entity1736 and @entity227 were corrected in all @entity1 . Mean follow-up was 24.6months. Six @entity1 had recurrence during the follow-up, and two @entity1 who had partial eyelid closure after the second stage surgery recovered in three months. @entity4457 , @entity940 , and strabismus were not improved after treatment. All of the @entity1 had excellent aesthetic improvement and corrected @entity1736 . CONCLUSIONS: Resection through a lower eyebrow and coronal incision and levator resection performed in two stages can quickly correct the @entity227 caused by periorbital microcystic @entity600 with @entity1736 . Intralesional @entity1732 injection is a promising adjunctive therapy for residual or recurrent lesions after surgery.

title: Management of periorbital microcystic XXXX with @entity1736 : Surgical treatment combined with intralesional @entity1732 injection.

answer: @entity600 :: (MESH:D000014,Disease) :: ['lymphatic malformation']


abstract: OBJECTIVES: Periorbital microcystic @entity600 ( @entity600 ) can cause severe symptoms, such as @entity1736 , @entity4457 , chemosis, strabismus, @entity4064 , and @entity1939 . The purpose of this study was to evaluate the clinical outcome in periorbital microcystic @entity600 @entity1 with @entity1736 who underwent surgical treatment combined with intralesional @entity1732 injection. @entity1 AND METHODS: A retrospective study including nine @entity1 diagnosed as periorbital microcystic @entity600 with @entity1736 was conducted. All of the @entity1 underwent surgical treatment and @entity1732 injection from January 2010 to January 2014. The lesion was resected through the lower eyebrow and/or a coronal incision at the first stage, and levator resection was performed at the second stage. Any persistent lesion or its recurrence was managed by intralesional @entity1732 injection. RESULTS: @entity1736 and @entity227 were corrected in all @entity1 . Mean follow-up was 24.6months. Six @entity1 had recurrence during the follow-up, and two @entity1 who had partial eyelid closure after the second stage surgery recovered in three months. @entity4457 , @entity940 , and strabismus were not improved after treatment. All of the @entity1 had excellent aesthetic improvement and corrected @entity1736 . CONCLUSIONS: Resection through a lower eyebrow and coronal incision and levator resection performed in two stages can quickly correct the @entity227 caused by periorbital microcystic @entity600 with @entity1736 . Intralesional @entity1732 injection is a promising adjunctive therapy for residual or recurrent lesions after surgery.

title: Management of periorbital microcystic @entity600 with XXXX : Surgical treatment combined with intralesional @entity1732 injection.

answer: @entity1736 :: (MESH:D001763,Disease) :: ['blepharoptosis']


abstract: BACKGROUND/PURPOSE: @entity1 with @entity209 ( @entity209 ) undergoing umbilical cord blood transplantation (UCBT) who are at risk for post-transplant failure to thrive may benefit from pretransplant @entity5274 ( @entity5274 ) placement. Here we sought to determine predictors of posttransplant failure to thrive. METHODS: A retrospective analysis was performed for IMD @entity1 who underwent UCBT at a single center from 2001 to 2011. @entity1 who received GTs were compared with controls. Multivariable logistic regression was used to determine significant predictors for @entity5274 placement. Recursive partitioning was performed to determine appropriate cut-offs for significant continuous variables. RESULTS: Two hundred and seventeen @entity1 met inclusion criteria of which twenty-three were excluded due to @entity204 within one hundred days of transplant. Forty (20.6%) of the remaining @entity1 underwent a surgical @entity5274 placement. Multivariable logistic regression demonstrated that weight percentile at time of transplant was significantly associated with @entity5274 placement (Adjusted odds ratio (AOR): 0.87 per 10th percentile, p=0.022). Recursive partitioning demonstrated that the 40th weight percentile at time of transplant was an optimal cut-off for predicting @entity5274 placement. CONCLUSIONS: @entity1 preparing for umbilical cord transplantation who are below the 40th percentile for weight may benefit from pre-emptive @entity5274 placement prior to transplant.

title: Predictors of gastrostomy placement in @entity1 with XXXX treated by umbilical cord blood transplantation.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Children']

entities_list: @entity5274 :: ('MESH:D005184', 'Disease') :: ['gastrostomy tube', 'GT']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['IMDs', 'inherited metabolic diseases']

answer: @entity209 :: (MESH:D008659,Disease) :: ['inherited metabolic diseases']


abstract: BACKGROUND/PURPOSE: @entity1 with @entity209 ( @entity209 ) undergoing umbilical cord blood transplantation (UCBT) who are at risk for post-transplant failure to thrive may benefit from pretransplant @entity5274 ( @entity5274 ) placement. Here we sought to determine predictors of posttransplant failure to thrive. METHODS: A retrospective analysis was performed for IMD @entity1 who underwent UCBT at a single center from 2001 to 2011. @entity1 who received GTs were compared with controls. Multivariable logistic regression was used to determine significant predictors for @entity5274 placement. Recursive partitioning was performed to determine appropriate cut-offs for significant continuous variables. RESULTS: Two hundred and seventeen @entity1 met inclusion criteria of which twenty-three were excluded due to @entity204 within one hundred days of transplant. Forty (20.6%) of the remaining @entity1 underwent a surgical @entity5274 placement. Multivariable logistic regression demonstrated that weight percentile at time of transplant was significantly associated with @entity5274 placement (Adjusted odds ratio (AOR): 0.87 per 10th percentile, p=0.022). Recursive partitioning demonstrated that the 40th weight percentile at time of transplant was an optimal cut-off for predicting @entity5274 placement. CONCLUSIONS: @entity1 preparing for umbilical cord transplantation who are below the 40th percentile for weight may benefit from pre-emptive @entity5274 placement prior to transplant.

title: Predictors of gastrostomy placement in XXXX with @entity209 treated by umbilical cord blood transplantation.

answer: @entity1 :: (9606,Species) :: ['children']


abstract: BACKGROUND: A healthy Nordic dietary pattern has shown beneficial effects in relation to several @entity102 . However, no study has evaluated the association between a healthy Nordic food index (HNFI) and risk of @entity0 . METHODS: We conducted a prospective cohort study including 44,296 @entity1 , aged 29-49 at baseline in 1991-1992, who completed a food frequency questionnaire at baseline, and have been followed up ever since, through the Swedish @entity5 Registry and Cause of Death Registry. Each @entity1 was assigned a HNFI score ranging from 0 to 6. We calculated multivariable relative risks (RRs) and 95  % confidence intervals (CIs) using Poisson regression models with attained age as the underlying timescale. The association between the HNFI and risk of @entity0 was assessed both overall, by menopausal status and by hormone receptor status. RESULTS: A total of 1,464 @entity0 cases were diagnosed during a median follow-up time of 20  years. A higher adherence to the HNFI was not associated with a lower risk of @entity0 overall, nor of varied hormone receptor status, or when we examining premenopausal and postmenopausal @entity1 separately. The multivariable RRs (95  % CI) for @entity0 per 1-point increment in the HNFI were 1.02 (95  % CI 0.98-1.06) for all @entity1 , 1.01 (95  % CI 0.95-1.08) for premenopausal @entity1 , and 1.02 (95  % CI 0.97-1.07) for postmenopausal @entity1 . CONCLUSION: Adherence to a HNFI was not associated with @entity0 incidence in this cohort of relatively young @entity1 , regardless of menopausal status or hormone receptor status.

title: Adherence to a healthy Nordic food index and XXXX risk: results from a Swedish cohort study.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic diseases']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: BACKGROUND: Major life-threatening complications secondary to cisplatin-based chemotherapy are rare in @entity1 with @entity5 ( @entity5 ). The incidence of complications increases with dosage of chemotherapy and with a variety of @entity1 -related as well as disease-related conditions. We here report the first case of @entity5 experiencing as many as four major complications most of which can be explained by the conjunction of several predispositions. CASE PRESENTATION: A 48  year old @entity1 with @entity4797 and bulky retroperitoneal and mediastinal metastases underwent cisplatin based chemotherapy. During the third cycle of chemotherapy, he developed @entity715 of the central venous port device, subtotal @entity1188 , and Bleomycin induced @entity55 (BIP). Three months after completion of therapy, he was struck by @entity1188 . Genetic testing then revealed heterozygote mutation of @entity5337 ( @entity5337 ). He received full-dose warfarin anticoagulation treatment and steroid treatment for BIP. 18  months thereafter, the @entity1 is still disease-free, oncologically. @entity16 have disappeared, but @entity358 persists with a vital capacity of 50%. CONCLUSION: The unique co-incidence of four major complications occurring in this @entity1 were obviously triggered by the genetically determined predisposition of the @entity1 to @entity715 events ( @entity5337 ). Additionally, several @entity1 -related and disease-related conditions contributed to the unique pattern of complications, i.e. (1) the slightly advanced age (48  years), (2) the @entity558 caused by the disease of @entity5 , (3) the central venous port device, (4) retroperitoneal bulky metastasis, and (5) cisplatin chemotherapy. Whether or not @entity5337 contributed to the @entity3794 as well, remains elusive. Practically, in the case of one major vascular complication during cisplatin chemotherapy at standard dose, genetic testing for hereditary @entity49 should be considered. Thus, precautions for preventing further complications could be initiated.

title: XXXX mutation triggering four major complications to standard dose cisplatin-chemotherapy for @entity4797 : a case report.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity558 :: ('MESH:C536528', 'Disease') :: ['prothrombotic condition']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonitis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['testicular germ cell tumour', 'GCT', 'cancer']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['Neurological symptoms']

entities_list: @entity3794 :: ('MESH:D011658', 'Disease') :: ['pulmonary fibrosis']

entities_list: @entity49 :: ('MESH:D019851', 'Disease') :: ['thrombophilia']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['thalamic infarction', 'splenic infarction']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary dysfunction']

entities_list: @entity4797 :: ('MESH:D018239', 'Disease') :: ['testicular seminoma']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'thrombotic']

answer: @entity5337 :: (2153,Gene) :: ['Factor V Leiden']


abstract: BACKGROUND: Major life-threatening complications secondary to cisplatin-based chemotherapy are rare in @entity1 with @entity5 ( @entity5 ). The incidence of complications increases with dosage of chemotherapy and with a variety of @entity1 -related as well as disease-related conditions. We here report the first case of @entity5 experiencing as many as four major complications most of which can be explained by the conjunction of several predispositions. CASE PRESENTATION: A 48  year old @entity1 with @entity4797 and bulky retroperitoneal and mediastinal metastases underwent cisplatin based chemotherapy. During the third cycle of chemotherapy, he developed @entity715 of the central venous port device, subtotal @entity1188 , and Bleomycin induced @entity55 (BIP). Three months after completion of therapy, he was struck by @entity1188 . Genetic testing then revealed heterozygote mutation of @entity5337 ( @entity5337 ). He received full-dose warfarin anticoagulation treatment and steroid treatment for BIP. 18  months thereafter, the @entity1 is still disease-free, oncologically. @entity16 have disappeared, but @entity358 persists with a vital capacity of 50%. CONCLUSION: The unique co-incidence of four major complications occurring in this @entity1 were obviously triggered by the genetically determined predisposition of the @entity1 to @entity715 events ( @entity5337 ). Additionally, several @entity1 -related and disease-related conditions contributed to the unique pattern of complications, i.e. (1) the slightly advanced age (48  years), (2) the @entity558 caused by the disease of @entity5 , (3) the central venous port device, (4) retroperitoneal bulky metastasis, and (5) cisplatin chemotherapy. Whether or not @entity5337 contributed to the @entity3794 as well, remains elusive. Practically, in the case of one major vascular complication during cisplatin chemotherapy at standard dose, genetic testing for hereditary @entity49 should be considered. Thus, precautions for preventing further complications could be initiated.

title: @entity5337 mutation triggering four major complications to standard dose cisplatin-chemotherapy for XXXX : a case report.

answer: @entity4797 :: (MESH:D018239,Disease) :: ['testicular seminoma']


abstract: PURPOSE: The aim of this study was to compare multidetector CT (MDCT), MRI, and FDG PET/CT imaging for the @entity298 ( @entity298 ) in @entity43 . @entity1 AND METHODS: Fifteen @entity1 with @entity43 and suspected @entity298 underwent MDCT, MRI, and FDG PET/CT, shortly before surgery. Nine abdominopelvic regions were defined according to the peritoneal @entity5 index. We applied lesion size scores on MDCT and MR and measured FDG PET/CT standard uptake. We blindly read MDCT, MR, and PET/CT before joint review and comparison with histopathology. Receiver operating characteristics analysis was performed. RESULTS: Ten @entity1 had @entity298 (67%). Altogether, 135 abdominopelvic sites were compared. Multidetector CT, MRI, and FDG PET/CT had a sensitivity of 96%, 98%, and 95%, and specificity was 92%, 84%, and 96%, respectively. Corresponding receiver operating characteristics area was 0.94, 0.90, and 0.96, respectively, without any significant differences between them (P = 0.12). FDG PET/CT detected supradiaphragmatic disease in 3 @entity1 (20%) not seen by MDCT or MRI. CONCLUSIONS: Although MRI had the highest sensitivity and FDG PET/CT had the highest specificity, no significant differences were found between the 3 techniques. Thus, MDCT, as the fastest, most economical, and most widely available modality, is the examination of choice, if a stand-alone technique is required. If inconclusive, PET/CT or MRI may offer additional insights. Whole-body FDG PET/CT may be more accurate for supradiaphragmatic metastatic extension.

title: XXXX in Primary @entity43 : Comparison Between MDCT, MRI, and 18F-FDG PET/CT.

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'PATIENTS']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity298 :: ('MESH:D010538', 'Disease') :: ['detection of peritoneal carcinomatosis', 'PC']

answer: @entity298 :: (MESH:D010538,Disease) :: ['Peritoneal Carcinomatosis']


abstract: PURPOSE: The aim of this study was to compare multidetector CT (MDCT), MRI, and FDG PET/CT imaging for the @entity298 ( @entity298 ) in @entity43 . @entity1 AND METHODS: Fifteen @entity1 with @entity43 and suspected @entity298 underwent MDCT, MRI, and FDG PET/CT, shortly before surgery. Nine abdominopelvic regions were defined according to the peritoneal @entity5 index. We applied lesion size scores on MDCT and MR and measured FDG PET/CT standard uptake. We blindly read MDCT, MR, and PET/CT before joint review and comparison with histopathology. Receiver operating characteristics analysis was performed. RESULTS: Ten @entity1 had @entity298 (67%). Altogether, 135 abdominopelvic sites were compared. Multidetector CT, MRI, and FDG PET/CT had a sensitivity of 96%, 98%, and 95%, and specificity was 92%, 84%, and 96%, respectively. Corresponding receiver operating characteristics area was 0.94, 0.90, and 0.96, respectively, without any significant differences between them (P = 0.12). FDG PET/CT detected supradiaphragmatic disease in 3 @entity1 (20%) not seen by MDCT or MRI. CONCLUSIONS: Although MRI had the highest sensitivity and FDG PET/CT had the highest specificity, no significant differences were found between the 3 techniques. Thus, MDCT, as the fastest, most economical, and most widely available modality, is the examination of choice, if a stand-alone technique is required. If inconclusive, PET/CT or MRI may offer additional insights. Whole-body FDG PET/CT may be more accurate for supradiaphragmatic metastatic extension.

title: @entity298 in Primary XXXX : Comparison Between MDCT, MRI, and 18F-FDG PET/CT.

answer: @entity43 :: (MESH:D010051,Disease) :: ['Ovarian Cancer Staging']